{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T16:25:05Z","timestamp":1761409505404,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515012368"],"award-info":[{"award-number":["2021A1515012368"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.pan.2023.12.008","type":"journal-article","created":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T09:55:29Z","timestamp":1704016529000},"page":"241-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase II study of SOXIRI (S-1\/oxaliplatin\/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma"],"prefix":"10.1016","volume":"24","author":[{"given":"Fenghua","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xujia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaozhen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruojun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guifang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pan.2023.12.008_bib1","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S1470-2045(19)30795-8","article-title":"Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future","volume":"21","author":"Christenson","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.pan.2023.12.008_bib2","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1016\/S1470-2045(17)30842-2","article-title":"Biomarkers for subtypes of pancreatic ductal adenocarcinoma","volume":"18","author":"Venkatesan","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.pan.2023.12.008_bib3","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J\u00a0Clin Oncol : official journal of the American Society of Clinical Oncology"},{"issue":"18","key":"10.1016\/j.pan.2023.12.008_bib4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.pan.2023.12.008_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.pan.2023.12.008_bib6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","article-title":"Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators","volume":"7","author":"Shirasaka","year":"1996","journal-title":"Anti Cancer Drugs"},{"issue":"Suppl 3","key":"10.1016\/j.pan.2023.12.008_bib7","doi-asserted-by":"crossref","first-page":"S646","DOI":"10.1245\/s10434-011-2140-2","article-title":"Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection","volume":"19","author":"Kondo","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"10041","key":"10.1016\/j.pan.2023.12.008_bib8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"13","key":"10.1016\/j.pan.2023.12.008_bib9","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J\u00a0Clin Oncol : official journal of the American Society of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.pan.2023.12.008_bib10","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J\u00a0Clin Oncol : official journal of the American Society of Clinical Oncology"},{"issue":"Pt 1","key":"10.1016\/j.pan.2023.12.008_bib11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.semcancer.2019.03.004","article-title":"The role of SOX family members in solid tumours and metastasis","volume":"67","author":"Grimm","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.pan.2023.12.008_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-015-2928-z","article-title":"Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1\/oxaliplatin\/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma","volume":"77","author":"Yanagimoto","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.pan.2023.12.008_bib13","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0900","article-title":"Phase II study of the triple combination chemotherapy of SOXIRI (S-1\/Oxaliplatin\/Irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma","volume":"24","author":"Akahori","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.pan.2023.12.008_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231186029","article-title":"Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer","volume":"15","author":"Li","year":"2023","journal-title":"Therapeutic Advances In Medical Oncology"},{"issue":"12","key":"10.1016\/j.pan.2023.12.008_bib15","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1245\/s10434-013-3161-9","article-title":"Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma","volume":"20","author":"Van Buren","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.pan.2023.12.008_bib16","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/sj.bjc.6603168","article-title":"Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer","volume":"94","author":"Nakamura","year":"2006","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.pan.2023.12.008_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000089997","article-title":"A\u00a0phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer","volume":"69","author":"Ueno","year":"2005","journal-title":"Oncology"},{"issue":"9","key":"10.1016\/j.pan.2023.12.008_bib18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","article-title":"Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study)","volume":"11","author":"Muro","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.pan.2023.12.008_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1054\/bjoc.2000.1236","article-title":"Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group","volume":"83","author":"Ohtsu","year":"2000","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.pan.2023.12.008_bib20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1054\/bjoc.2001.2031","article-title":"Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer","volume":"85","author":"Kawahara","year":"2001","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.pan.2023.12.008_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10147-004-0381-9","article-title":"Alternate-day oral therapy with TS-1 for advanced gastric cancer","volume":"9","author":"Arai","year":"2004","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.pan.2023.12.008_bib22","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10147-008-0780-4","article-title":"Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in\u00a0vitro and in\u00a0vivo","volume":"13","author":"Arai","year":"2008","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.pan.2023.12.008_bib23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00280-017-3250-8","article-title":"Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer","volume":"79","author":"Yamaue","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.pan.2023.12.008_bib24","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/cas.12501","article-title":"Phase II study of FOLFIRINOX for chemotherapy-na\u00efve Japanese patients with metastatic pancreatic cancer","volume":"105","author":"Okusaka","year":"2014","journal-title":"Cancer Sci"},{"issue":"8","key":"10.1016\/j.pan.2023.12.008_bib25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nrclinonc.2011.107","article-title":"Chemotherapy: metastatic pancreatic cancer--is FOLFIRINOX the new standard?","volume":"8","author":"Saif","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.pan.2023.12.008_bib26","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000365537","article-title":"Improvements in health-related quality of life by comprehensive cancer pain therapy: a pilot study with breast cancer outpatients under palliative chemotherapy","volume":"37","author":"Puetzler","year":"2014","journal-title":"Oncol Res Treat"},{"issue":"10","key":"10.1016\/j.pan.2023.12.008_bib27","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrc3131","article-title":"Perineural invasion and associated pain in pancreatic cancer","volume":"11","author":"Bapat","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pan.2023.12.008_bib28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.critrevonc.2016.01.006","article-title":"Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review","volume":"99","author":"Kristensen","year":"2016","journal-title":"Crit Rev Oncol-Hematol"},{"key":"10.1016\/j.pan.2023.12.008_bib29","first-page":"135","volume":"vol. 181","author":"Ozaka","year":"2023"},{"issue":"18","key":"10.1016\/j.pan.2023.12.008_bib30","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/0006-2952(82)90279-9","article-title":"Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway","volume":"31","author":"El Sayed","year":"1982","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.pan.2023.12.008_bib31","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jamaoncol.2015.6315","article-title":"Response rate as a regulatory end point in single-arm studies of advanced solid tumors","volume":"2","author":"Oxnard","year":"2016","journal-title":"JAMA Oncol"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390323018823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390323018823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T16:20:05Z","timestamp":1761409205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390323018823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1424390323018823"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2023.12.008","relation":{},"ISSN":["1424-3903"],"issn-type":[{"type":"print","value":"1424-3903"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of SOXIRI (S-1\/oxaliplatin\/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2023.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of IAP and EPC.","name":"copyright","label":"Copyright"}]}}